Open Access Full Text Article

CORRIGENDUM

CD40L inhibits cell growth of THP-1 cells by suppressing the PI3K/Akt pathway [Corrigendum]

Feng Z, Chen Q, Ren M, Tian Z, Gong Y. *OncoTargets Ther.* 2019;12:3011–3017.

The author list and affiliations should be:

Zhongxin Feng,¹ Qi Chen,¹ Mingqiang Ren,¹ Zuguo Tian,¹ Yuping Gong²

¹Department of Hematology, Affiliated Hospital of Zunyi Medical University, Zunyi, People's Republic of China; ²Department of Hematology, West China School of Medicine/West China Hospital, Sichuan University, Chengdu, People's Republic of China The corresponding author should be:

Correspondence: Qi Chen Department of Hematology, Affiliated Hospital of Zunyi Medical University, No149, Dalian Road, Guizhou, Zunyi 563003, People's Republic of China Tel +86 851 2860 8538 Fax +86 851 2860 8538 Email zyfychenqi@163.com

OncoTargets and Therapy

Dovepress

4223

Publish your work in this journal

OncoTargets and Therapy is an international, peer-reviewed, open access journal focusing on the pathological basis of all cancers, potential targets for therapy and treatment protocols employed to improve the management of cancer patients. The journal also focuses on the impact of management programs and new therapeutic agents and protocols on patient perspectives such as quality of life, adherence and satisfaction. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit http://www.dovepress.com/ testimonials.php to read real quotes from published authors.

Submit your manuscript here: https://www.dovepress.com/oncotargets-and-therapy-journal



OncoTargets and Therapy 2019:12 4223

© 2019 Feng et al. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission for Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 42 and 5 of our Terms (https://www.dovepress.com/terms.php).